Table 2.

Uni- and multivariable analyses of predictors of disease-free survival at 5 years

	Univariable analysis		Multivariable analysis
	HR (95% CI)	p value	HR (95% CI)	p value
ypN0	Reference	0.964	Reference	0.613
ypNitc/mi	1.02 (0.52–1.99)	<0.001	1.38 (0.40–4.79)	0.031
ypN1-3	1.89 (1.43–2.50)		1.78 (1.06–3.00)
Age (per year increment)	1.02 (1.01–1.02)	0.001	1.01 (0.99–1.02)	0.479
ypT-stage
T0 or Tis	Reference		Reference
T1-2	1.88 (1.31–2.70)	0.001	2.73 (1.39–5.39)	0.004
T3-4	3.74 (2.53–5.54)	<0.001	4.71 (2.35–9.43)	<0.001
Tumor type
Ductal	Reference		Reference
Lobular	0.78 (0.53–1.14)	0.193	1.11 (0.59–2.07)	0.751
Other	0.89 (0.69–1.15)	0.386	0.89 (0.58–1.37)	0.595
Tumor grade
3 versus 1–2	1.64 (1.22–2.20)	0.001	1.69 (1.19–2.40)	0.004
Subtypes
ER+PR+Her2−: yes versus noa	0.63 (0.50–0.80)	<0.001
ER+PR−Her2−: yes versus noa	1.32 (0.99–1.75)	0.057
ER+Her2+: yes versus noa,b	0.63 (0.47–0.85)	0.002
ER−Her2+: yes versus nob	1.20 (0.95–1.53)	0.129
Triple negative: yes versus no	1.94 (1.46–2.32)	<0.001	1.16 (0.69–1.93)	0.577
Trastuzumab
Yes versus no	0.81 (0.65–1.00)	0.052	0.76 (0.47–1.23)	0.263
Endocrine therapy
Yes versus no	0.57 (0.47–0.69)	<0.001	0.55 (0.36–0.85)	0.007
Radiation therapy
Yes versus no	1.09 (0.78–1.52)	0.626	0.74 (0.45–1.23)	0.251

HR hazard ratio, ypN0 axillary pathologic complete response, ypNitc/mi axillary residual isolated tumor cells or micrometastases, ypN1-3 axillary residual macrometastases, ypT-stage pathologic tumor stage after neo-adjuvant chemotherapy, ER estrogen, PR progesterone, Her2 human epidermal growth factor receptor 2

^aExcluded from multivariable analysis due to collinearity with endocrine therapy

^bExcluded from multivariable analysis due to collinearity with trastuzumab